NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) announced that the Company will complete its clinical Phase 2 study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results